Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions

M. Turek; R. Gogal; C. Saba; M. L. Vandenplas; J. Hill; B. Feldhausser; J. Lawrence

doi:10.1016/j.rvsc.2014.02.001

Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions

M. Turek, R. Gogal, C. Saba, M. L. Vandenplas, J. Hill, B. Feldhausser, J. Lawrence

Veterinary Clinical Sciences

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC₅₀ values of 5.5-8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0-12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.

Original language	English (US)
Pages (from-to)	304-307
Number of pages	4
Journal	Research in veterinary science
Volume	96
Issue number	2
DOIs	https://doi.org/10.1016/j.rvsc.2014.02.001
State	Published - Apr 2014

Bibliographical note

Funding Information:
This work was supported by the Morris Animal Foundation (MAF). The MAF had no involvement in design, analysis or interpretation of the study.

Funding Information:
The authors would like to thank Dr. Deborah Keys for statistical analyses and Dr. Colin Mansfield (medical writer at AB Science) for critical review of the manuscript. This work was supported by the Morris Animal Foundation .

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Keywords

Cat
Clonogenic
Masitinib
Radiation
Sarcoma
Tyrosine kinase inhibitor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.rvsc.2014.02.001

OpenUrl availability

Full text

Cite this

@article{7a077c6ba23245089310fe4a72909b52,

title = "Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions",

abstract = "Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5-8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0-12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.",

keywords = "Cat, Clonogenic, Masitinib, Radiation, Sarcoma, Tyrosine kinase inhibitor",

author = "M. Turek and R. Gogal and C. Saba and Vandenplas, {M. L.} and J. Hill and B. Feldhausser and J. Lawrence",

note = "Funding Information: This work was supported by the Morris Animal Foundation (MAF). The MAF had no involvement in design, analysis or interpretation of the study. Funding Information: The authors would like to thank Dr. Deborah Keys for statistical analyses and Dr. Colin Mansfield (medical writer at AB Science) for critical review of the manuscript. This work was supported by the Morris Animal Foundation . Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "2014",

month = apr,

doi = "10.1016/j.rvsc.2014.02.001",

language = "English (US)",

volume = "96",

pages = "304--307",

journal = "Research in veterinary science",

issn = "0034-5288",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions

AU - Turek, M.

AU - Gogal, R.

AU - Saba, C.

AU - Vandenplas, M. L.

AU - Hill, J.

AU - Feldhausser, B.

AU - Lawrence, J.

N1 - Funding Information: This work was supported by the Morris Animal Foundation (MAF). The MAF had no involvement in design, analysis or interpretation of the study. Funding Information: The authors would like to thank Dr. Deborah Keys for statistical analyses and Dr. Colin Mansfield (medical writer at AB Science) for critical review of the manuscript. This work was supported by the Morris Animal Foundation . Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 2014/4

Y1 - 2014/4

N2 - Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5-8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0-12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.

AB - Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition assays with mean IC50 values of 5.5-8.6μM. Clonogenic assays were performed to determine the effect of masitinib and radiation on cell survival. Single dose radiation (0-12Gy) experiments were carried out under normal growth conditions in control ISS cells and in cells incubated with 1 or 6μM masitinib for 72h prior to irradiation. Radiation administered either alone or in combination with masitinib induced a dose-dependent reduction in clonogenic survival. Survival from the combined masitinib and radiation treatment was not significantly different from that of radiation alone. Results suggest that masitinib does not directly enhance ISS cell radiosensitivity under normal in vitro conditions, although this does not preclude the utility of further investigations to assess sensitization properties under altered conditions.

KW - Cat

KW - Clonogenic

KW - Masitinib

KW - Radiation

KW - Sarcoma

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84896494849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896494849&partnerID=8YFLogxK

U2 - 10.1016/j.rvsc.2014.02.001

DO - 10.1016/j.rvsc.2014.02.001

M3 - Article

C2 - 24602916

AN - SCOPUS:84896494849

SN - 0034-5288

VL - 96

SP - 304

EP - 307

JO - Research in veterinary science

JF - Research in veterinary science

IS - 2

ER -

Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this